FDA grants priority review for Lilly's ramucirumab in gastric cancer
This article was originally published in Scrip
Executive Summary
The US FDA has granted priority review to Lilly's biologic license application (BLA) for ramucirumab (IMC-1121B), a vascular endothelial growth factor (VEGF) inhibitor, as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.